高级搜索

小细胞肺癌患者外周血胃泌素释放肽前体mRNA的检测及其临床意义

Detection of ProGRP mRNA in Peripheral Blood and Its Signifi cance in Patients with Small Cell Lung Cancer

  • 摘要: 目的 探讨小细胞肺癌(small cell lung cancer,SCLC)患者外周血胃泌素释放肽前体(progastrin-releasing peptide,ProGRP) mRNA表达水平和血清ProGRP水平的相关性及其与临床病理因素、近期疗效的关系。方法 收集61例初治小细胞肺癌患者,分别于第1次和第3次化疗前抽取外周静脉血,采用实时荧光定量反转录聚合酶链反应(reverse transcriptase-polymerase chain reaction,RTPCR) 法检测ProGRP mRNA的表达水平,同时采用酶联免疫吸附(ELISA)法测定患者血清ProGRP水平进行比较。结果 SCLC患者外周血ProGRP mRNA表达水平、血清ProGRP水平均与原发肿瘤大小、临床分期及远处转移相关(P<0.05)。直线相关分析表明外周血ProGRP mRNA表达水平与血清ProGRP 水平具有相关性(R2=0.34,P<0.05)。化疗2周期后,PR+CR组患者外周血ProGRP mRNA表达水平及血清ProGRP水平均较治疗前明显下降(P<0.05),而SD+PD组患者化疗前后两者水平均无明显下降(P>0.05)。结论 ProGRP mRNA可作为检测SCLC患者外周血循环肿瘤细胞的标志物,定期监测外周血ProGRP mRNA表达水平变化有助于评估化疗疗效和预测预后;血清ProGRP水平检测也可以作为SCLC疗效判断和预后评估指标,且检测方法简便易行。

     

    Abstract: Objective To investigate the relationship between the expression of pro-gastrin-releasing peptide(ProGRP) mRNA in peripheral blood and serum ProGRP protein and their association with pathological factors and chemotherapy response in patients with small cell lung cancer(SCLC). Methods The expression of ProGRP mRNA was detected by real-time reverse transcriptase-polymerase chain reaction (RT-PCR) in peripheral blood from 61 patients with SCLC before the first and the third chemotherapy. Serum ProGRP protein was also determined by enzyme linked immunosorbent assay (ELISA). Results ProGRP mRNA expression and the level of serum ProGRP protein were related to primary tumor size, clinical stages and distant metastasis(P<0.05). Linear correlation analysis revealed then there was a correlation between ProGRP mRNA expression in peripheral blood and serum ProGRP protein level (R2=0.34, P<0.05). Both levels of ProGRP mRNA and serum ProGRP protein in PR and CR cases were signifi cantly declined following the second cycle of chemotherapy (P<0.05). There was no obvious decrease in SD and PD cases before or after treatment (P>0.05). Conclusion ProGRP mRNA could be used as a marker in the detection of circulating tumor cells in SCLC, and regular quantifi cation of ProGRP mRNA in peripheral blood may be useful to evaluate the therapeutic effi ciency and predict prognosis of SCLC patients. Serum ProGRP may also serve as a prognostic marker and be used in the assessment of therapeutic response in SCLC patients and the method is simple and feasible.

     

/

返回文章
返回